PDCD1 and small cell lung carcinoma: Thus, there is an urgent need for novel and highly effective therapeutic options for extensive stage SCLC (ES-SCLC) considering that the median overall survival (OS) for relapsed disease is approximately 4.0-5.6 months in the real world, regardless of prior PD-1 or PD-L1 inhibitor use.6